WASHINGTON (Reuters) -U.S. lawmakers on Thursday asked Pfizer Inc for information on alleged comments by a former executive ...

A former Pfizer scientist said the timing of the 2020 vaccine results “wasn’t a coincidence,” according to allegations ...

Pfizer (PFE) stock draws public scrutiny as a House probe gathers new allegations regarding the company's COVID-19 vaccine ...

For years, U.S. vaccine experts have issued a universal recommendation for Covid vaccines. That could change soon.

A decades-long scientific challenge in HIV vaccine development has been finding a way to train the immune system to produce ...

Researchers aim to develop a universal vaccine platform that could protect against both COVID-19 and influenza without annual ...

A new vaccine developed by Moderna aims to protect against both flu and COVID-19 with just one shot. Early studies suggest ...

A novel AI-driven method helps scientists stay ahead of viral evolution by engineering synthetic spike proteins that ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year ...

NIH involvement through more stages of development could give the government greater influence on any vaccine’s eventual ...

A landmark study by scientists at the University of Oxford, has unveiled crucial insights into the way that COVID-19 vaccines mitigate severe illness in those who have been vaccinated.